What is idelalisib: a practical review

Idelalisib is a potent oral selective inhibitor of phosphatidylinositol 3‐kinase p110δ, approved in Australia for the treatment of relapsed chronic lymphocytic leukaemia and small cell lymphocytic lymphoma in combination with rituximab or ofatumumab in patients for whom chemoimmunotherapy is not considered suitable. In the most recent edition of the Journal of Pharmacy Practice and Research, respected oncology pharmacist review practical aspects of idelalisib.